Anthracycline News and Research

RSS
Anthracycline is a type of antibiotic that comes from certain types of Streptomyces bacteria. Anthracyclines are used to treat many types of cancer. Anthracyclines damage the DNA in cancer cells, causing them to die. Daunorubicin, doxorubicin, and epirubicin are anthracyclines.
Cell Therapeutics reports cardiac safety results from phase II trial of pixantrone in CHOP-R regimen

Cell Therapeutics reports cardiac safety results from phase II trial of pixantrone in CHOP-R regimen

CTI to conduct phase II study of pixantrone in patients with HER2-negative breast cancer

CTI to conduct phase II study of pixantrone in patients with HER2-negative breast cancer

Abraxis Bioscience first-quarter ABRAXANE revenue increases to $87.9 million

Abraxis Bioscience first-quarter ABRAXANE revenue increases to $87.9 million

Immunogen reports a net loss of $12.1 million in third quarter 2010

Immunogen reports a net loss of $12.1 million in third quarter 2010

Genentech submits sBLA for Herceptin plus chemotherapy for advanced HER2-positive stomach cancer

Genentech submits sBLA for Herceptin plus chemotherapy for advanced HER2-positive stomach cancer

EMEA PDCO recommends Cell Therapeutics to submit updated Pediatric Investigation Plan for pixantrone

EMEA PDCO recommends Cell Therapeutics to submit updated Pediatric Investigation Plan for pixantrone

ABRAXANE-bevacizumab combination therapy may exhibit potential in treatment of triple-negative breast cancers

ABRAXANE-bevacizumab combination therapy may exhibit potential in treatment of triple-negative breast cancers

Updated survival data from Phase I/II trial of nab-paclitaxel, gemcitabine combination for pancreatic cancer

Updated survival data from Phase I/II trial of nab-paclitaxel, gemcitabine combination for pancreatic cancer

Cell Therapeutics receives feedback regarding proposed filing of MAA for pixantrone

Cell Therapeutics receives feedback regarding proposed filing of MAA for pixantrone

Abraxis BioScience to present updated survival findings from ABRAXANE Phase I/II trial at 101st AACR meeting

Abraxis BioScience to present updated survival findings from ABRAXANE Phase I/II trial at 101st AACR meeting

Cell Therapeutics receives FDA Complete Response Letter for Pixuvri NDA

Cell Therapeutics receives FDA Complete Response Letter for Pixuvri NDA

Eisai Europe seeks EMA approval of eribulin mesylate for locally advanced or metastatic breast cancer

Eisai Europe seeks EMA approval of eribulin mesylate for locally advanced or metastatic breast cancer

Eisai seeks simultaneous approval of eribulin mesylate in U.S., EU and Japan

Eisai seeks simultaneous approval of eribulin mesylate in U.S., EU and Japan

Abnormality on chromosome 17 helps detect breast cancer tumour's response to anthracyclines

Abnormality on chromosome 17 helps detect breast cancer tumour's response to anthracyclines

CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval

CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval

Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint

Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint

Challenges in treating AML and recent updates to NCCN Guidelines presented at NCCN Annual Conference

Challenges in treating AML and recent updates to NCCN Guidelines presented at NCCN Annual Conference

SpePharm Holding acquires global rights to Savene from TopoTarget

SpePharm Holding acquires global rights to Savene from TopoTarget

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

FDA approves Rituxan-FC combination therapy for CLL

FDA approves Rituxan-FC combination therapy for CLL